CG Oncology Inc's shares surged by 32.41%, reaching a 52-week high, following positive developments in their clinical trial timelines.
The significant stock surge is attributed to CG Oncology's announcement of an expedited topline data readout for the PIVOT-006 clinical trial, now expected in the first half of 2026. This advancement reflects strong market confidence in the company's future prospects, as the trial aims to address the urgent need for new therapies in the intermediate-risk non-muscle invasive bladder cancer space. The earlier data release is expected to attract more investor interest, further propelling the company's growth.
This rapid progress in clinical development not only positions CG Oncology favorably within the industry but also enhances its financing capabilities, potentially influencing treatment standards for non-muscle invasive bladder cancer and prompting other companies to accelerate their R&D efforts.
Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 75.17 USD with a low forecast of 55.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 75.17 USD with a low forecast of 55.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 55.100
Low
55.00
Averages
75.17
High
108.00
Current: 55.100
Low
55.00
Averages
75.17
High
108.00
Truist
Buy
maintain
$62 -> $66
2026-01-09
Reason
Truist
Price Target
$62 -> $66
AI Analysis
2026-01-09
maintain
Buy
Reason
Truist raised the firm's price target on CG Oncology to $66 from $62 and keeps a Buy rating on the shares after the company provided an updated timeline for PIVOT-006 topline data, now expected in 1H26. The accelerated pivotal readout was driven by "the unprecedented early completion of enrollment," which the firm views as potentially reflecting physician buy-in for Creto, the analyst tells investors in a research note. The firm noted its peak revenue estimate of roughly $1.4B for Creto and a favorable setup, with surveillance as the control arm and a less crowded competitive landscape.
Wedbush
Outperform
initiated
$70
2025-12-11
Reason
Wedbush
Price Target
$70
2025-12-11
initiated
Outperform
Reason
Wedbush initiated coverage of CG Oncology with an Outperform rating and $70 price target. The firm notes the company is developing an oncolytic virus, cretostimogene grenadenorepvec, for the treatment of NMIBC. Wedbush believes cretostimogene's mechanisms of action, including selective killing of tumor cells, and triggering of an anti-tumor immune response are critical to driving robust efficacy across high-risk BCG-unresponsive non-muscle invasive bladder cancer settings. Furthermore, the firm thinks cretostimogene's favorable safety/tolerability profile and intravesical administration will allow for broad uptake in a large commercial market as a differentiated treatment option. Wedbush looks forward to completion of a BLA submission in 2026, as well as meaningful clinical readouts that it expects to drive shares higher, ahead of a potential commercial launch.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CGON
Unlock Now
Truist
Gregory Renza
Buy
initiated
$62
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$62
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of CG Oncology with a Buy rating and $62 price target. The firm views Creto's high complete response rates, favorable tolerability, and differentiated durability as key attributes that could support robust market positioning for the company, the analyst tells investors in a research note. The potential expansion into intermediate-risk/IR NMIBC, or Non-Muscle Invasive Bladder Cancer, and additional high-risk settings represent a strategic approach that could broaden Creto's commercial opportunity, given the ongoing BCG - Bacillus Calmette Guerin - shortage, Truist added.
RBC Capital
Outperform
maintain
$53 -> $61
2025-11-17
Reason
RBC Capital
Price Target
$53 -> $61
2025-11-17
maintain
Outperform
Reason
RBC Capital raised the firm's price target on CG Oncology to $61 from $53 and keeps an Outperform rating on the shares. CG Oncology's Q3 update highlighted that its BLA filing is now underway, easing concerns about timing and keeping the company on track for a potentially strong non-muscle invasive bladder cancer launch with a more than $2.7B opportunity, the analyst tells investors in a research note. With additional Q4 catalysts ahead and a favorable safety/efficacy profile despite competitive questions, the outlook remains compelling, RBC says.
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
